

TABLE 80: INCLUDED STUDY CHARACTERISTICS – TREATMENT-EXPERIENCED (N = 12)

AUTHOR, YEAR, STUDY NAME (IF AVAILABLE)	TOTAL N	POPULATION	TREATMENTS	COUNTRIES	RANDOMIZED (Y/N)	GENOTYPE			
						1	2	3	4
Included in the NMA									
Afdhal et al., 2014 ION-2	441	≥ 18 years Genotype 1 Approximately 20% may have compensated cirrhosis	SOF12 + LDV12 SOF12 + LDV12 + RBV12 SOF24 + LDV24 SOF24 + LDV24 + RBV24	USA	Yes	Y			
Andreone et al., 2014 PEARL-II	95	18 to 70 years Genotype 1b No cirrhosis	PAR/RIT12 + OMB12 + DAS12	Europe, Puerto Rico, Turkey, USA	Yes	Y			
Bourlière et al., 2015 SIRIUS	155	≥ 18 years Genotype 1	SOF24 + LDV24 SOF12 + LDV12 + RBV12	France	Yes	Y			
Jensen et al., 2015 HALLMARK-QUAD	398	≥ 18 years Genotype 1 or 4	DCV24 + ASU24 + PR24	Canada, USA, Europe, Republic of Korea, Mexico, Taiwan	No	Y			Y
Lawitz et al., 2014	47	≥ 18 years Genotype 2 or 3	SOF12 + PR12	USA	No		Y	Y	
Lok et al., 2014	101	18 to 70 years Genotype 1 No evidence of liver cirrhosis	DCV24 + ASU24 DCV24 + ASU24 + PR24	USA, Puerto Rico, France	Yes	Y			

AUTHOR, YEAR, STUDY NAME (IF AVAILABLE)	TOTAL N	POPULATION	TREATMENTS	COUNTRIES	RANDOMIZED (Y/N)	GENOTYPE				
						1	2	3	4	
Osinusi et al., 2014 SYNERGY	14	≥ 18 years Genotype 1 or 4 With or without cirrhosis	SOF12 + LDV12	USA	No	Y				
Pol S et al., 2015	80	18 to 70 years Genotype 1 No cirrhosis	SOF12 + PR12	USA, Europe, New Zealand	No	Y				
Reddy et al., 2015 ATTAIN	771	≥ 18 years Genotype 1	SIM12 PR48 T12 PR48 q8	Canada, USA, Australia, Israel, S. America, Europe	Yes	Y				
Wyles et al., 2015	51	≥ 18 years Genotype 1	SOF12 + LDV12 + RBV12	USA	No	Y				
Zeuzem et al., 2014 SAPPHERE-II	395	18 to 70 years Genotype 1 No evidence of liver cirrhosis	PAR/RIT12 + OMB12 + DAS12 + RBV12	Europe, N. America, Australia	Yes	Y				
Not included in the NMA										
Forns et al., 2015 C-SALVAGE	79	≥ 18 years Genotype 1	GRZ12 + ELB12 + RBV12	USA, Austria, Israel, Spain	No	Y				

ASU = asunaprevir; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; q8 = every 8 hours; LDV = ledipasvir; NMA = network meta-analysis; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.